Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours - PubMed (original) (raw)

Comparative Study

doi: 10.1007/BF00686639.

Affiliations

• PMID: 7987993
• DOI: 10.1007/BF00686639

Comparative Study

Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours

L M Ching et al. Cancer Chemother Pharmacol. 1994.

Abstract

The investigational antitumour agent 5,6-dimethyl-xanthenone-4-acetic acid (5,6-MeXAA) induced dose-dependent haemorrhagic necrosis of colon 38 tumours to a similar extent to that induced using bacterial lipopolysaccharide (LPS). TNF-alpha activity in serum and mRNA for TNF-alpha in splenocytes were induced over a broad range of LPS doses, whereas with 5,6-MeXAA, induction occurred only at concentrations approaching the maximum tolerated dose. At concentrations that provided similar degrees of haemorrhagic necrosis, the levels of serum TNF-alpha induced using 5,6-MeXAA were 100-fold lower than those obtained with LPS, indicating that haemorrhagic necrosis was not directly correlated with TNF-alpha levels. There was also no correlation between the degree of tumour necrosis and the duration of growth delay. Treatment with LPS did not induce a significant delay in growth, despite extensive tumour haemorrhagic necrosis, whereas with 5,6-MeXAA, treatments that improved the cure rate did not necessarily give longer growth delays. Therapy using a combination of sub-optimal doses of both compounds was synergistic for the induction of serum TNF-alpha and message for TNF-alpha but was not synergistic for antitumour efficacy. Thus, no correlation is evident between cure rates, duration of growth delay, haemorrhagic necrosis and TNF-alpha induction by 5,6-MeXAA or LPS.

PubMed Disclaimer

Similar articles

• Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
  Cao Z, Joseph WR, Browne WL, Mountjoy KG, Palmer BD, Baguley BC, Ching LM. Cao Z, et al. Br J Cancer. 1999 May;80(5-6):716-23. doi: 10.1038/sj.bjc.6690415. Br J Cancer. 1999. PMID: 10360649 Free PMC article.
• Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid.
  Ching LM, Xu ZF, Gummer BH, Palmer BD, Joseph WR, Baguley BC. Ching LM, et al. Br J Cancer. 1995 Aug;72(2):339-43. doi: 10.1038/bjc.1995.335. Br J Cancer. 1995. PMID: 7640215 Free PMC article.
• Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid.
  Baguley BC, Cole G, Thomsen LL, Li Z. Baguley BC, et al. Cancer Chemother Pharmacol. 1993;33(1):77-81. doi: 10.1007/BF00686027. Cancer Chemother Pharmacol. 1993. PMID: 8269593
• Relationship of tumour necrosis factor and endotoxin to macrophage cytotoxicity, haemorrhagic necrosis and lethal shock.
  Rothstein JL, Schreiber H. Rothstein JL, et al. Ciba Found Symp. 1987;131:124-39. doi: 10.1002/9780470513521.ch9. Ciba Found Symp. 1987. PMID: 3330008 Review.
• Small-molecule cytokine inducers causing tumor necrosis.
  Baguley BC. Baguley BC. Curr Opin Investig Drugs. 2001 Jul;2(7):967-75. Curr Opin Investig Drugs. 2001. PMID: 11757800 Review.

Cited by

• Temporal aspects of the action of ASA404 (vadimezan; DMXAA).
  Baguley BC, Siemann DW. Baguley BC, et al. Expert Opin Investig Drugs. 2010 Nov;19(11):1413-25. doi: 10.1517/13543784.2010.529128. Expert Opin Investig Drugs. 2010. PMID: 20964495 Free PMC article. Review.
• Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid.
  Moilanen E, Thomsen LL, Miles DW, Happerfield DW, Knowles RG, Moncada S. Moilanen E, et al. Br J Cancer. 1998;77(3):426-33. doi: 10.1038/bjc.1998.68. Br J Cancer. 1998. PMID: 9472639 Free PMC article.
• Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
  Cao Z, Joseph WR, Browne WL, Mountjoy KG, Palmer BD, Baguley BC, Ching LM. Cao Z, et al. Br J Cancer. 1999 May;80(5-6):716-23. doi: 10.1038/sj.bjc.6690415. Br J Cancer. 1999. PMID: 10360649 Free PMC article.
• Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid.
  Ching LM, Xu ZF, Gummer BH, Palmer BD, Joseph WR, Baguley BC. Ching LM, et al. Br J Cancer. 1995 Aug;72(2):339-43. doi: 10.1038/bjc.1995.335. Br J Cancer. 1995. PMID: 7640215 Free PMC article.
• Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.
  Philpott M, Baguley BC, Ching LM. Philpott M, et al. Cancer Chemother Pharmacol. 1995;36(2):143-8. doi: 10.1007/BF00689199. Cancer Chemother Pharmacol. 1995. PMID: 7767951

References

1. 1. J Natl Cancer Inst. 1988 Oct 5;80(15):1226-31 - PubMed
2. 1. Eur J Cancer. 1991;27(1):79-83 - PubMed
3. 1. Br J Cancer. 1988 Mar;57(3):277-80 - PubMed
4. 1. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4148-52 - PubMed
5. 1. J Immunol. 1988 May 1;140(9):3261-5 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database